All rights reserved. No reuse allowed without permission.

## 1 **Title: The** *NR5A1/SF-1* **variant p.Gly146Ala cannot explain the phenotype of individuals with a**

# 2 **difference of sex development.**

3

1 Idoia Martinez de Lapiscina<sup>1,2,3,4,5,6</sup>, Chrysanthi Kouri<sup>1,2,7</sup>, Josu Aurrekoetxea<sup>8,9</sup>, Mirian Sanchez<sup>3</sup>, Rawda 5 Naamneh Elzenaty<sup>1,2,7</sup>, Kay-Sara Sauter<sup>1,2</sup>, Núria Camats<sup>5,10</sup>, Gema Grau<sup>3,6,11</sup>, Itxaso Rica<sup>3,4,5,6,11</sup>, Amaia 6 Rodriguez<sup>3,11</sup>, Amaia Vela<sup>3,4,5,6,11</sup>, Alicia Cortazar<sup>4,12</sup>, M. Concepción Alonso-Cerezo<sup>13</sup>, Pilar Bahillo<sup>14</sup>, 7 Laura Berthod<sup>15</sup>, Isabel Esteva<sup>16</sup>, Luis Castaño<sup>3,4,5,6,9,11,\*</sup>, Christa E. Flück<sup>1,2,\*</sup>

8

<sup>1</sup> 9 Pediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics, Inselspital, Bern 10 University Hospital, University of Bern, Bern, Switzerland. <sup>2</sup> Department for BioMedical Research, 11 University of Bern, Bern, Switzerland. <sup>3</sup> Research into the genetics and control of diabetes and other 12 endocrine disorders, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, 13 Barakaldo, Spain. <sup>4</sup> CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto 14 de Salud Carlos III, Madrid, Spain. <sup>5</sup> CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos 15 III, Madrid, Spain. <sup>6</sup>Endo-ERN, Amsterdam, The Netherlands. <sup>7</sup>Graduate School for Cellular and 16 Biomedical Sciences, University of Bern, Bern, Switzerland. <sup>8</sup> Research group of Medical Oncology, 17 Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Spain. <sup>9</sup> University 18 of the Basque Country (UPV-EHU), Leioa, Spain. <sup>10</sup> Growth and Development group, Vall d'Hebron 19 Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain. <sup>11</sup> Department of 20 Pediatric Endocrinology, Cruces University Hospital, Barakaldo Spain. <sup>12</sup> Endocrinology Department, 21 Cruces University Hospital, Barakaldo, Spain. <sup>13</sup>La Princesa University Hospital, Madrid, Spain. 22 <sup>14</sup> Pediatric Endocrinology Unit, Department of Pediatrics, Clinic University Hospital of Valladolid, 23 Valladolid, Spain. <sup>15</sup> Pediatric Endocrinology Department, Marques de Valdecilla University Hospital, 24 Santander, Spain. <sup>16</sup> Endocrinology Section, Gender Identity Unit, Regional University Hospital of 25 Malaga, Malaga, Spain.

26 \*Co-last authors

27

28 Corresponding author: Idoia Martinez de Lapiscina, PhD; idoia.martinezdelapiscina@unibe.ch

- 29 Phone Nr: +41316641475
- 30

31 **Short title:** Role of *NR5A1*/SF-1 p.Gly146Ala in DSD

- 32
- 33

#### All rights reserved. No reuse allowed without permission.

## **Abstract**

 Steroidogenic factor 1 (SF-1, *NR5A1*) plays an important role in human sex development. Variants of *NR5A1/*SF-1 may cause mild to severe differences of sex development (DSD) or may be found in healthy carriers. So far, the broad DSD phenotypic variability associated *NR5A1*/SF-1 variants remains a conundrum. The *NR5A1*/SF-1 variant c.437G>C/p.Gly146Ala is common in individuals with a DSD and has been suggested to act as a susceptibility factor for adrenal disease or cryptorchidism. However, as the allele frequency in the general population is high, and as functional testing of the p.Gly146Ala variant *in vitro* revealed inconclusive results, the disease-causing effect of this variant has been questioned. However, a role as a disease modifier in concert with other gene variants is still possible given that oligogenic inheritance has been described in patients with *NR5A1*/SF-1 gene variants. Therefore, we performed next generation sequencing in DSD individuals harboring the *NR5A1*/SF-1 p.Gly146Ala variant to search for other DSD-causing variants. Aim was to clarify the function of this variant for the phenotype of the carriers. We studied 14 pediatric DSD individuals who carried the p.Gly146Ala variant. Panel and whole-exome sequencing was performed, and data were analyzed with a specific data filtering algorithm for detecting variants in *NR5A1*- and DSD-related genes. The phenotype of the studied individuals ranged from scrotal hypospadias and ambiguous genitalia in 46,XY DSD to typical male external genitalia and ovotestes in 46,XX DSD patients. Patients were of African, Spanish, and Asian origin. Of the 14 studied subjects, five were homozygous and nine heterozygous for the *NR5A1*/SF-1 p.Gly146Ala variant. In ten subjects we identified either a clearly pathogenic DSD gene variant (e.g. in *AR*, *LHCGR*) or one to four potentially deleterious variants that likely explain the observed phenotype alone (e.g. in *FGFR3*, *CHD7*, *ADAMTS16*). Our study shows that most individuals carrying the *NR5A1*/SF-1 p.Gly146Ala variant, harbor at least one other deleterious gene variant which can explain the DSD phenotype. This finding confirms that the p.Gly146Ala variant of *NR5A1/SF-1* may not contribute to the pathogenesis of DSD and qualifies as a benign polymorphism. Thus, individuals, in whom the *NR5A1*/SF-1 p.Gly146Ala gene variant has been identified as the underlying genetic cause for their DSD in the past, should be re-evaluated with a next-generation sequencing method to reveal the real genetic diagnosis.

### All rights reserved. No reuse allowed without permission.

### **Introduction**

 Typical sex development depends on the specific interactions of many genes and pathways in a defined spatiotemporal sequence. Any perturbation in this very complex biological event, which involves genetic and hormonal processes, may result in atypical sex development and leads to a broad range of differences of sex development (DSD) in humans, also known as variations of sex characteristics (VSC) (1). The *NR5A1* gene, which encodes the steroidogenic factor 1 (SF-1), regulates multiple genes implicated in adrenal development, gonadal determination and differentiation, steroidogenesis, and reproduction (2). Since the identification of the first *NR5A1*/SF-1 variation in a 46,XY patient with primary adrenal failure and complete gonadal dysgenesis (3), the gonadal and reproductive phenotype associated with *NR5A1*/SF-1 variants has broadened including 46,XY and 46,XX cases with sex reversal to minor untypicalities such as hypospadias or even healthy carriers, whereas adrenal failure has only been found in very rare cases (4, 5).

 Currently, 291 different *NR5A1*/SF-1 variants are reported in the Human Gene Mutation Database (HGMD, October 2022). Variants include missense/nonsense, indels, small insertions/deletions, complete gene deletions or splice-site variants that are scattered throughout the whole gene without obvious hot spots. According to ACMG (American College of Medical Genetics and Genomics) classification (6), described variants may qualify as (likely) pathogenic or (likely) benign, and several are variants of unknown significance (VUS).

 The nonsynonymous *NR5A1*/SF-1 c.437G>C/p.Gly146Ala (rs1110061) variant has been first described in a group of Japanese patients presenting with a series of adrenal diseases such as Cushing's 82 syndrome or non-functioning adrenocortical adenoma (7). In this context, WuQiang et al. reported that the p.Gly146Ala variant slightly impairs the transactivation ability of adrenal and ovary specific gene promoters but does not affect cofactor interaction and cellular localization (7). Later, it has been proposed to act as a susceptibility factor for cryptorchidism (8), isolated micropenis (9, 10), spermatogenic failure (11, 12), primary ovarian insufficiency (POI) (13) and type 2 diabetes (14). The p.Gly146Ala variant is common among individuals with a 46,XY DSD with a prevalence varying between 6.8 and 31% (15, 16). However, the minor allele frequency (MAF) (C allele) is also high in the overall control population (23.5%, gnomAD v3.1.2). Specifically, its MAF is increased approximately by 1.3-3-fold in the East Asian and the African control populations, whereas it is only present in 1% of the European control population (gnomAD v3.1.2). Moreover, *in vitro* studies of transcriptional activity of the *NR5A1*/SF-1 p.Gly146Ala variant on several target promoters in various cell models found unaltered wild-type functionality (15, 17). In fact, some patients who carry severe, pathogenic *NR5A1*/SF-1 variants in compound heterozygous state with the p.Gly146Ala variant, do not phenotypically differ from individuals carrying the severe variant only (5, 16-22). The DSD causing

All rights reserved. No reuse allowed without permission.

 effect of the *NR5A1*/SF-1 p.Gly146Ala variant is therefore in doubt. However, given that oligogenic inheritance has been suggested for explaining the broad phenotype observed in individuals and families with *NR5A1*/SF-1 gene variants (23-29), the p.Gly146Ala variant might play a role as co- regulator or disease modifier of sexual development. The aim of this study was therefore, to elucidate the role of the *NR5A1/*SF-1 p.Gly146Ala variant on sexual development. We studied 14 DSD patients carrying this variant by next generation sequencing (NGS). Specifically, we searched for other DSD-causing variants and their pathogenicity in order to assess the effect of the *NR5A1/*SF-1 p.Gly146Ala variant on the phenotype of its carriers.

# **Patients and Methods**

# **Patients and ethical approval**

 We recruited 14 pediatric DSD individuals carrying the *NR5A1/*SF-1 p.Gly146Ala variant from a larger cohort of 125 DSD patients collected at the Biocruces Bizkaia Health Research Institute (Barakaldo, Spain). Clinical data were provided by the caring clinicians (Table 1 and S2 table). The study was approved by the ethics committee for clinical research of Euskadi (CEIC-E), Spain. Written informed consent was provided by the parents of the studied children.

- Ten 46,XY DSD and four 46,XX DSD patients carrying the p.Gly146Ala variant in the *NR5A1*/SF-1 gene
- were analyzed using whole exome sequencing (WES) or a targeted gene panel comprised of 48 genes
- associated with sex determination, sex differentiation and hypogonadism (Supplementary table 1).
- 

### **Genetic analysis**

 Genomic DNA from the patients was extracted from peripheral blood leukocytes using the MagPurix 12S system (Zinexts Life Science Corp.). DNA purity and concentration were determined using a Qubit 2.0 fluorometer (Thermo Fisher Scientific).

 Initial characterization for the *NR5A1/*SF-1 p.Gly146Ala variant was done by a DSD specific panel. Additional NGS was performed by WES (Figure 1A). For WES, libraries were prepared using the Illumina DNA/RNA Prep Tagmentation PCR reagents (Illumina) and Illumina Exome Panel (CEX) according to the manufacturer's instructions. The resulting libraries were subjected to paired-end sequencing on a NovaSeq 6000 System (Illumina). Raw data were then converted to FastQ files for computational analysis, which included read alignment to the human genome reference sequence (GRCh38), duplicate marking, base quality score recalibration, indel realignment, and variant calling with an in-127 house bioinformatics pipeline using BWA-MEM (30) and GATK (31) software. Variants were annotated with wANNOVAR (32) and filtration process of the exonic variants was performed using R software (R 4.2.0). Variant filtration was performed following specific steps as given in Figure 1B.

 These steps included the filtration of WES data by a DSD- and *NR5A1*-related gene list. These disease- tailored lists were updated from previously reported work (DSD-gene list, N=584; *NR5A1*-related gene list, N=628) (22, 32) (Figure 1 Step a). Then, we kept the resulting variants with all type of predicted consequences (e.g. nonsynonymous, frameshift deletion, stop/gain), but synonymous, and with a number of reads above or equal to 20 (33) (Figure 1 steps b and c). Next, we filtered to include variants with a MAF≤0.01 according to gnomAD (v3.1.2) and depending on the origin and karyotype of the patient (Figure 1 step d). In step e, we confirmed the correct annotation, location of variants and zygosity by checking their alignment data in IGV (Integrative Genomics Viewer). Finally, we predicted the possible effect of the identified variant (see below) (Figure 1 step f). Variants were confirmed by visual examination using the IGV (Integrative Genomics Viewer) browser (34, 35).

 For the targeted DSD-gene panel analysis, preparation of the libraries and sequencing have been described elsewhere (24). For variant filtration after panel analysis, same steps b to f were followed (Figure 1B).

## *In silico* **analyses and variant classification**

 We predicted the possible effect of identified nonsynonymous genetic variants on the structure and function of the protein using Polyphen-2, (Polymorphism Phenotyping v2), Panther (Protein ANalysis THrough Evolutionary Relationships), SNPs and GO, CADD (Combined Annotation Dependent Depletion) and the calibrated scores given by VarSome (36) for Revel (Rare Exome Variant Ensemble Learner), SIFT (Scale-invariant feature transform), Provean (Protein Variation Effect Analyzer), Mutation taster and M-CAP (Mendelian Clinically Applicable Pathogenicity) (see Supplementary table 3). Variants were classified for pathogenicity according to the standards and guidelines of the ACMG (6) using VarSome. We considered variants as candidates when classified as pathogenic, likely pathogenic or as VUS by the ACMG criteria or when classified as pathogenic or VUS by at least 7 out of 9 prediction programs. Previously reported clinical associations were searched in ClinVar and HGMD databases. In addition, the literature (e.g. PubMed) was searched for evidence of relationship with DSD, sex development and the specific clinical phenotype of each study subject. We explored the possible disease-causing variants' combinations using ORVAL (Oligogenic Resource for Variant AnaLysis) (37).

## **Results and Discussion**

 In a random cohort of 125 subjects with a DSD, we identified the *NR5A1*/SF-1 p.Gly146Ala variant in 14 individuals (11.2%). The prevalence in 46,XY DSD subjects was 10.1% (10/99), and was in line with previously reported prevalence in this population (15, 16). Prevalence was higher in 46,XX DSD (4/24,

All rights reserved. No reuse allowed without permission.

 16.7%). Of the 14 studied subjects, five were homozygous and nine heterozygous for the *NR5A1*/SF-1 p.Gly146Ala variant. The phenotype of the individuals ranged from typical for karyotype to mild and severe atypical in 46,XY as well as opposite sex in both 46,XY and 46,XX (Figure 2). Patients were of African (8/14), Spanish (4/14) and Asian (2/14) origin. A summary of the clinical and biochemical characteristics of the patients is given in Table 1 and Supplementary table 2. An overview of the identified genes of our study subjects that likely play a role for the DSD phenotype in a concerted way is given in Figure 3. In this Figure 3 the identified variants are shown within the network of established genes of sex determination and differentiation.

 NGS performed in DSD individuals harboring the p.Gly146Ala variant in *NR5A1*/SF-1 revealed several deleterious/candidate variants that potentially explain the phenotype of the patients. Overall, we identified either a known pathogenic DSD variant or one to four potentially deleterious/candidate variants in 10 out of the 14 DSD individuals analyzed. A detailed summary of identified variants in other DSD-related genes is shown in Table 2 (further details in Supplementary tables 3 and 4).

177 In three patients we detected variants in known DSD-causing genes with our targeted gene panel, e.g. *LHCGR*, *WT1*, and *AR*. In 11 patients WES was performed and variants were filtered by candidate gene lists (Figure 1). Overall, the NGS analysis identified 63 variants categorized as (likely) pathogenic or VUS in 57 different genes, however further review of evidence of correlation with DSD, sex development and phenotype of each patient with literature reduced this number to 20 potentially deleterious/candidate variants in 18 genes in 10 subjects. In nine 46,XY DSD individuals 1-4 variants were found in a total of 16 genes, while one 46,XX DSD person revealed two variants in two different genes (Table 2). All variants, identified either by gene panel or WES, but one (e.g. *LHCGR*), were detected in heterozygosis or hemizygosis. Details of the rejected variants are given in Supplementary table 4.

 In **patient 1** two frameshift deletions in genes *FGFR3* (c.1633\_1634del; p.Cys545Hisfs\*17) and *INSR* (c.660\_661del; p.Pro220Hisfs\*4) and a stop-gain variant in *ADAMTS16* (c.1822\_1823del; p.His608\*) were found and predicted to be likely pathogenic by the ACMG criteria. *FGFR3* is essential for testicular development in humans (38), while *INSR* and *ADAMTS16* are needed in murine genitourinary development and testicular differentiation, respectively (39, 40). Variants in *ADAMTS16* have also been reported in heterozygosis in two 46,XY females with complete gonadal dysgenesis and a 46,XY DSD patient with ambiguous genitalia (41). Testing for a digenic combination network with ORVAL showed no variant interaction between *ADAMTS16* and *FGFR3*.

 We detected four heterozygous missense variants in four genes in **patient 3**. These were *GLI2* (c.3528G>T; p.Gln1176His), *CDH7* (c.1623C>A; p.His541Gln), *MYO7A* (c.2882G>A; p.Gly961Asp) and *VDR* (c.176C>T; p.Thr59Ile). The variant in *GLI2* (c.3528G>T; p.Gln1176His) was rated as pathogenic by

All rights reserved. No reuse allowed without permission.

 most of the *in silico* prediction tools and variants in additional genes were rated as VUS when analyzing according to pathogenicity guidelines. Variants in *GLI2* have been described in syndromic DSD patients together with short stature, primary hypogonadism, heart and craniofacial anomalies and 46,XY gonadal dysgenesis (42), as well as in 46,XY non-syndromic DSD manifesting with female external genitalia or with ambiguous genitalia (23, 43, 44). Variants in *CHD7* have been previously associated with a broad range of 46,XY DSD phenotypes, including males with hypospadias or micropenis and individuals with female external genitalia (27, 45). *MYO7A* is overexpressed in male supporting cells during gonadal development (46) and has been shown to be a SRY and SOX9 target gene (47), but, in DSD individuals it has been identified only in combination with *MAMLD1* (44, 48). Finally, *VDR* plays a 207 dominant role in male fertility as Vdr $\frac{1}{2}$  mice show abnormal gonads in both sexes and variable reproductive phenotypes such as reduced sperm count (49). In humans, two polymorphisms in *VDR* were associated with female idiopathic infertility only (50). Fertility of patient 3 has not been assessed yet, and we cannot exclude a role of the *VDR* variant in his DSD phenotype. Network analysis by ORVAL predicts a pathogenic gene network between *CHD7*, *MYO7A* and *GLI2* (Supplementary figure 1A).

 A heterozygous missense c.182C>A; p.Pro61Gln variant in Neuropilin 1 (*NRP1)* gene was found in **patient 6**. NRP1 interacts with Sema3A which is essential for the development of the GnRH neuron system (51). Loss of Sema3a (Semaphorin 3A) signaling in mice results in reduced gonadal size and recapitulates the features of Kallmann syndrome (52). In humans, variants in *NRP1* have been identified in a 46,XY DSD subject with female external genitalia (45) and a 46,XY male presenting with penoscrotal hypospadias, in whom other genetic variants were identified, among them a variant in *MAMLD1,* a known DSD-related gene (48).

 In 46,XY **patient 8** with a phenotype of opposite sex a homozygous, inactivating variant in *LHCGR* (c.757T>C; p.Ser253Pro) was found. This variant has been previously reported to severely reduce the 221 signal transduction activity of the LH receptor and therefore leads to the complete form of Leydig cell hypoplasia (LCH) as seen in patient 8 (53).

 A novel, likely pathogenic p.Met255Lys (c.764T>A) missense variant in exon 2 of *WT1* was found in **patient 9,** who had precocious puberty and presented with a pituitary adenoma and hearing loss. *WT1* is associated with 46,XY gonadal dysgenesis in syndromes including Denys-Drash or Frasier (54), but more recently *WT1* variants have also been detected in individuals with isolated DSD, such as ambiguous genitalia (45, 55, 56) or gonadal dysgenesis. WT1 acts as a transcriptional repressor or activator on many target genes, such as *LHB* (Luteinizing Hormone Subunit Beta), which encodes the beta subunit of LH (luteinizing hormone), responsible for testosterone production in males during puberty. Variants of *WT1* may therefore affect the transcription of LHβ and thereby lead to altered 231 puberty timing as observed in patient 9. In fact, in mouse cell models, WT1 regulates LHB transcription

 and two splice variants (-KTS/+KTS) were already shown to have positive and negative roles in this regulation (57).

 A missense variant in *COL27A1* (c.3715C>T; p.Arg1239Trp) and a frameshift insertion in *TYRO3* (c.666\_667insCACTGCCTGCAGCCCCCTTCAACATCACC; p.Ala223HisfsTer21) were found in **patient 10**. Both variants were categorized as VUS and were detected in heterozygosis. In mice, *Col27a1* is highly expressed in XY somatic supporter cells compared to XX during the earliest stages of gonad development (58). *Col27a1* has been identified as a SRY target gene in the embryonic mouse gonads at E11.5 by ChIP-Chip experiments (47). Similarly, *Tyro3* is overexpressed in male somatic cells (59), and is regulated by SOX9 (47). Protein truncating variants of *TYRO3* were found in individuals with idiopathic hypogonadotropic hypogonadism establishing a role of this gene in reproductive development (60). Taken together, the data suggest that both *COL27A1* and *TYRO3* genes are part of the genetic network underlying the early stages of mammalian fetal gonadal development, and thus genetic changes are likely causing the ovotesticular DSD phenotype in patient 10. However, a gene interaction between *COL27A1* and *TYRO3* was not predicted by ORVAL.

 In 46,XY **patient 11** with a distal hypospadias, one missense variant in the *SOX8* (c.676A>C; p.Thr226Pro) gene was detected. It was identified in heterozygosis and was classified as VUS. *SOX8* is involved in early testis determination (61). *SOX8* gene variants are associated with a range of 249 phenotypes including 46,XY DSD and human reproductive anomalies in males and females (62). Single- nucleotide variants (SNV) associated with 46,XY gonadal dysgenesis are mostly located in the HMG- box of SOX8 (43), while those reported in infertile patients flank the HMG-box or localize to one of the transactivation domains (TA) (62). However, more recently, a missense variant in the TA2 region of SOX8 was identified in a 46,XY patient with gonadal dysgenesis (43). The novel c.676A>C; p.Thr226Pro variant is located in the first TA of the protein. *In vitro* studies have shown impaired cellular localization in some mutant proteins located in this functional domain of SOX8. Therefore, this missense variant likely explains the genital phenotype observed in patient 11. Biochemical assessment (age range 11- 15) of the HPG axis was normal and pubertal development was ongoing (Tanner 3-4).

 Four heterozygous VUS or likely pathogenic variants were identified in **patient 12** with a severe 46,XY DSD phenotype. These were *POR* (c.1679C>T; p.Thr560Met), *PKD1* (c.2624C>T; p.Pro875Leu), *SRCAP* (c.7142G>A; p.Arg2381His) and *SOX9* (c.710dup; p.Pro238Thrfs\*14). The involvement of *POR* and *SOX9* in sexual development is well known and several sequence variants have been described in 46,XY DSD patients (27, 47, 63). *Pkd1* is critical for epididymal epithelium development and for maintaining mice male reproductive tract (64). *PKD1* variants have not been related to DSD yet, but they cause autosomal dominant polycystic kidney disease (ADPKD), which involves reproductive tract abnormalities and infertility in males (65). Therefore, a role of *PKD1* variants in DSD seems possible.

Likewise, the role of *SRCAP* in sex differentiation and development is unknown. However, this is the

 second 46,XY DSD patient in whom a gene variant is identified (42). According to ORVAL analysis, oligogenic pathogenicity is predicted by combination of variants in a gene network including *POR*, *PKD1* and *SRCAP* (Supplementary figure 1B).

 In **patient 13**, we identified an *AR* variant (c.2323C>T; p.Arg775Cys) previously reported in a patient 271 with Complete Androgen Insensitivity Syndrome (CAIS) (66). Because the patient presented with a typical CAIS phenotype, it seems plausible that this hemizygous *AR* variant is fully responsible for the DSD.

- **Patient 14**, with a severe 46,XY phenotype, harbored two heterozygous missense variants in *MYO7A* and *SOX8* genes. Both were categorized as VUS by the ACMG. As in patient 11, the *SOX8* variant (c.694A>C; p.Lys232Gln) was also located in the TA1 domain of the protein. However, the phenotype of patient 14 was more severe, either caused by the *SOX8* variant alone or due to the digenic effect together with *MYO7A.* Importantly, the combination of variants in *SOX8* and *MYO7A* is predicted as disease-causing by ORVAL (Supplementary figure 1C). The combination of variants in *MYO7A* and *SOX8* in DSD was reported previously (44, 48), and suggests that the broad phenotype observed in DSD individuals might be explained by oligogenic origin (67).
- 

 In four patients carrying the heterozygous p.Gly146Ala *NR5A1* variant, the WES and specific data analysis revealed no other candidate genes explaining their DSD phenotype. Of these patients 2, 4 and 5 had a 46,XX karyotype and an opposite genital phenotype, and were assigned as males at birth, whereas patient 7 presented with a severe 46,XY DSD. None had other organ anomalies. Although NGS has facilitated the identification of the underlying genetic defects of DSD, about 50% of individuals with a 46,XY DSD remain without a molecular diagnosis with currently used methods (27). We used WES in our study, while other genetic studies also search for variants in noncoding, regulatory or intronic regions by whole genome sequencing (WGS). But even when using WGS, a considerable number of patients are reportedly unsolved (68). Thus, other factors such as environmental factors or epigenetic regulators have been suggested playing a role (68, 69). In addition, oligogenic or even polygenic inheritance might be considered for explaining the broad phenotypes seen in some individuals with a DSD (23-29, 48, 67, 70-73). In early days of genetic workup of DSD, patients were studied by candidate Sanger sequencing. In 46,XY DSD subjects typical candidates were the *AR*, *SRD5A2* and *NR5A1*/SF-1; and once a genetic variant was found, additional genes were not tested. Thus, some DSD patients that have been tested by the candidate approach may not have a correct diagnosis and need to be retested by NGS.

 In conclusion, NGS genetic analysis of DSD individuals carrying the p.Gly146Ala variant of the *NR5A1*/SF-1 gene revealed variants in other genes (likely) explaining their phenotype. These gene variants were either found in established DSD genes, were previously described or novel, and were (likely) disease-causing either in a monogenic or in a suggested oligogenic fashion. Although we were not able to find causal genetic variants in four out of 14 DSD individuals carrying the *NR5A1*/SF-1 p.Gly146Ala, our study supports the claim that this *NR5A1*/SF-1 variant is a benign polymorphism that does not play a role in the pathogenesis of DSD. Therefore, we strongly recommend reanalyzing DSD patients of whom phenotype has been thought to be explained by this variant in order to find the real underlying genetic cause.

## **Acknowledgement**

- The authors thank the patients and their families for participating in our research.
- 

### **Competing interests**

- The authors have declared that no competing interests exist.
- 

### **Funding**

- This work has been supported by the University of the Basque Country (UPV-EHU) (Spain) (IT1739-22)
- and by the Swiss National Science Foundation (320030-197725). IM is supported by a Postdoctoral
- Fellowship Grant from the Education Department of Basque Government (Spain). JA is supported by
- ASONMEC (Asociacion de Oncologia Medica del Hospital de Cruces) (Spain).
- 

### **Supporting information**

- S1 Table. Genes included in the customized DSD panel and their suggested role in DSD.
- S2 Table. Complete description of the phenotype and biochemical data of the DSD patients harbouring
- the NR5A1/SF-1 p.Gly146Ala variant.
- S3 Table 3. Gene variant characterization: allele frequency and disease prediction by ACMG classification and by different in silico programs
- aSpecific allele frequency for the origin and karyotype of the patient. bCADD phred score >20 indicates
- that the variant is predicted to be the 1% most deleterious substitution that you can do to the human
- genome.
- S4 Table. List of rejected variants identified in the DSD patients harbouring the NR5A1/SF-1
- p.Gly146Ala variant. Variants were discarded after filtering due to weak relation to DSD, zygosity or
- absence of correspondence to the phenotype.

- S1 Figure. Potential oligogenic interaction networks of DSD- and NR5A1-related genes identified in specific DSD individuals harbouring the NR5A1/SF-1 p.Gly146Ala variant. Networks were identified for patients 3, 12 and 14 respectively. To search for potential oligogenic disease networks, the Oligogenic Resource for Variant AnaLysis (ORVAL, https://orval.ibsquare.be/) was used. Nodes represent genes and edges connect two genes only, if between them there is at least one candidate disease-causing variant combination predicted by VarCoPP. The colour of the edge represents the pathogenicity score for that pair of genes. This score is represented in a colour range from brown (higher pathogenicity score) to yellow (lower pathogenicity score).
- 

All rights reserved. No reuse allowed without permission.

# **References**

 1. Eggers S, Ohnesorg T, Sinclair A. Genetic regulation of mammalian gonad development. Nature reviews Endocrinology. 2014;10(11):673-83. 2. Achermann JC, Ozisik G, Ito M, Orun UA, Harmanci K, Gurakan B, et al. Gonadal determination and adrenal development are regulated by the orphan nuclear receptor steroidogenic factor-1, in a dose-dependent manner. The Journal of clinical endocrinology and metabolism. 2002;87(4):1829-33. 3. Achermann JC, Ito M, Ito M, Hindmarsh PC, Jameson JL. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nature genetics. 1999;22(2):125-6. 4. Fabbri-Scallet H, de Sousa LM, Maciel-Guerra AT, Guerra-Júnior G, de Mello MP. Mutation update for the NR5A1 gene involved in DSD and infertility. Hum Mutat. 2020;41(1):58-68. 5. Domenice S, Machado AZ, Ferreira FM, Ferraz-de-Souza B, Lerario AM, Lin L, et al. Wide spectrum of NR5A1-related phenotypes in 46,XY and 46,XX individuals. Birth defects research Part C, Embryo today : reviews. 2016;108(4):309-20. 6. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in medicine : official journal of the American College of Medical Genetics. 2015;17(5):405-24. 7. WuQiang F, Yanase T, Wei L, Oba K, Nomura M, Okabe T, et al. Functional characterization of a new human Ad4BP/SF-1 variation, G146A. Biochem Biophys Res Commun. 2003;311(4):987-94. 8. Wada Y, Okada M, Fukami M, Sasagawa I, Ogata T. Association of cryptorchidism with Gly146Ala polymorphism in the gene for steroidogenic factor-1. Fertility and sterility. 2006;85(3):787-90. 9. Paris F, De Ferran K, Bhangoo A, Ten S, Lahlou N, Audran F, et al. Isolated 'idiopathic' micropenis: hidden genetic defects? Int J Androl. 2011;34(6 Pt 2):e518-25. 10. Wada Y, Okada M, Hasegawa T, Ogata T. Association of severe micropenis with Gly146Ala polymorphism in the gene for steroidogenic factor-1. Endocrine journal. 2005;52(4):445-8. 11. Bashamboo A, Ferraz-de-Souza B, Lourenço D, Lin L, Sebire NJ, Montjean D, et al. Human male infertility associated with mutations in NR5A1 encoding steroidogenic factor 1. Am J Hum Genet. 2010;87(4):505-12. 12. Röpke A, Tewes AC, Gromoll J, Kliesch S, Wieacker P, Tüttelmann F. Comprehensive sequence analysis of the NR5A1 gene encoding steroidogenic factor 1 in a large group of infertile males. European journal of human genetics : EJHG. 2013;21(9):1012-5. 13. Philibert P, Paris F, Lakhal B, Audran F, Gaspari L, Saâd A, et al. NR5A1 (SF-1) gene variants in a group of 26 young women with XX primary ovarian insufficiency. Fertility and sterility. 2013;99(2):484-9. 14. Liu W, Liu M, Fan W, Nawata H, Yanase T. The Gly146Ala variation in human SF-1 gene: its association with insulin resistance and type 2 diabetes in Chinese. Diabetes Res Clin Pract. 2006;73(3):322-8. 15. Camats N, Pandey AV, Fernández-Cancio M, Andaluz P, Janner M, Torán N, et al. Ten novel mutations in the NR5A1 gene cause disordered sex development in 46,XY and ovarian insufficiency in 46,XX individuals. The Journal of clinical endocrinology and metabolism. 2012;97(7):E1294-306. 16. Tantawy S, Mazen I, Soliman H, Anwar G, Atef A, El-Gammal M, et al. Analysis of the gene coding for steroidogenic factor 1 (SF1, NR5A1) in a cohort of 50 Egyptian patients with 46,XY disorders of sex development. European journal of endocrinology. 2014;170(5):759-67. 17. Reuter AL, Goji K, Bingham NC, Matsuo M, Parker KL. A novel mutation in the accessory DNA-binding domain of human steroidogenic factor 1 causes XY gonadal dysgenesis without adrenal insufficiency. European journal of endocrinology. 2007;157(2):233-8.

All rights reserved. No reuse allowed without permission.

 18. Köhler B, Lin L, Ferraz-de-Souza B, Wieacker P, Heidemann P, Schröder V, et al. Five novel mutations in steroidogenic factor 1 (SF1, NR5A1) in 46,XY patients with severe underandrogenization but without adrenal insufficiency. Hum Mutat. 2008;29(1):59-64.

 19. Hasegawa T, Fukami M, Sato N, Katsumata N, Sasaki G, Fukutani K, et al. Testicular dysgenesis without adrenal insufficiency in a 46,XY patient with a heterozygous inactive mutation of steroidogenic factor-1. The Journal of clinical endocrinology and metabolism. 2004;89(12):5930-5.

 20. Bertelloni S, Dati E, Baldinotti F, Toschi B, Marrocco G, Sessa MR, et al. NR5A1 gene mutations: clinical, endocrine and genetic features in two girls with 46,XY disorder of sex development. Hormone research in paediatrics. 2014;81(2):104-8.

 21. Woo KH, Cheon B, Kim JH, Cho J, Kim GH, Yoo HW, et al. Novel Heterozygous Mutations of NR5A1 and Their Functional Characteristics in Patients with 46,XY Disorders of Sex Development without Adrenal Insufficiency. Hormone research in paediatrics. 2015;84(2):116-23.

 22. Adamovic T, Chen Y, Thai HT, Zhang X, Markljung E, Zhao S, et al. The p.G146A and p.P125P polymorphisms in the steroidogenic factor-1 (SF-1) gene do not affect the risk for hypospadias in Caucasians. Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation. 2012;6(6):292-7.

 23. Camats N, Fernández-Cancio M, Audí L, Schaller A, Flück CE. Broad phenotypes in heterozygous NR5A1 46,XY patients with a disorder of sex development: an oligogenic origin? European journal of human genetics : EJHG. 2018;26(9):1329-38.

 24. Martínez de LaPiscina I, Mahmoud RA, Sauter KS, Esteva I, Alonso M, Costa I, et al. Variants of STAR, AMH and ZFPM2/FOG2 May Contribute towards the Broad Phenotype Observed in 46,XY DSD Patients with Heterozygous Variants of NR5A1. International journal of molecular sciences. 2020;21(22).

 25. Mazen I, Abdel-Hamid M, Mekkawy M, Bignon-Topalovic J, Boudjenah R, El Gammal M, et al. Identification of NR5A1 Mutations and Possible Digenic Inheritance in 46,XY Gonadal Dysgenesis. Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and

pathology of sex determination and differentiation. 2016;10(3):147-51.

 26. Werner R, Mönig I, Lünstedt R, Wünsch L, Thorns C, Reiz B, et al. New NR5A1 mutations and phenotypic variations of gonadal dysgenesis. PloS one. 2017;12(5):e0176720.

 27. Eggers S, Sadedin S, van den Bergen JA, Robevska G, Ohnesorg T, Hewitt J, et al. Disorders of 421 sex development: insights from targeted gene sequencing of a large international patient cohort. Genome biology. 2016;17(1):243.

 28. Robevska G, van den Bergen JA, Ohnesorg T, Eggers S, Hanna C, Hersmus R, et al. Functional characterization of novel NR5A1 variants reveals multiple complex roles in disorders of sex development. Hum Mutat. 2018;39(1):124-39.

426 29. Wang H, Zhang L, Wang N, Zhu H, Han B, Sun F, et al. Next-generation sequencing reveals genetic landscape in 46, XY disorders of sexual development patients with variable phenotypes. Human genetics. 2018;137(3):265-77.

 30. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26(5):589-95.

 31. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices

pipeline. Curr Protoc Bioinformatics. 2013;43(1110):11.0.1-.0.33.

 32. Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nat Protoc. 2015;10(10):1556-66.

 33. Meynert AM, Ansari M, FitzPatrick DR, Taylor MS. Variant detection sensitivity and biases in whole genome and exome sequencing. BMC Bioinformatics. 2014;15(1):247.

34. Arteche-López A, Ávila-Fernández A, Romero R, Riveiro-Álvarez R, López-Martínez MA,

Giménez-Pardo A, et al. Sanger sequencing is no longer always necessary based on a single-center

validation of 1109 NGS variants in 825 clinical exomes. Scientific reports. 2021;11(1):5697.

 35. De Cario R, Kura A, Suraci S, Magi A, Volta A, Marcucci R, et al. Sanger Validation of High- Throughput Sequencing in Genetic Diagnosis: Still the Best Practice? Frontiers in genetics. 2020;11:592588. 36. Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Albarca Aguilera M, Meyer R, et al. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35(11):1978-80. 37. Renaux A, Papadimitriou S, Versbraegen N, Nachtegael C, Boutry S, Nowé A, et al. ORVAL: a novel platform for the prediction and exploration of disease-causing oligogenic variant combinations. Nucleic Acids Res. 2019;47(W1):W93-w8. 38. Ewen KA, Olesen IA, Winge SB, Nielsen AR, Nielsen JE, Graem N, et al. Expression of FGFR3 during human testis development and in germ cell-derived tumours of young adults. Int J Dev Biol. 2013;57(2-4):141-51. 39. Pitetti JL, Calvel P, Zimmermann C, Conne B, Papaioannou MD, Aubry F, et al. An essential role for insulin and IGF1 receptors in regulating sertoli cell proliferation, testis size, and FSH action in mice. Molecular endocrinology (Baltimore, Md). 2013;27(5):814-27. 40. Jacobi CL, Rudigier LJ, Scholz H, Kirschner KM. Transcriptional regulation by the Wilms tumor protein, Wt1, suggests a role of the metalloproteinase Adamts16 in murine genitourinary development. J Biol Chem. 2013;288(26):18811-24. 41. Barseghyan H, Symon A, Zadikyan M, Almalvez M, Segura EE, Eskin A, et al. Identification of novel candidate genes for 46,XY disorders of sex development (DSD) using a C57BL/6J-Y (POS) mouse model. Biol Sex Differ. 2018;9(1):8. 42. Globa E, Zelinska N, Shcherbak Y, Bignon-Topalovic J, Bashamboo A, MсElreavey K. Disorders of Sex Development in a Large Ukrainian Cohort: Clinical Diversity and Genetic Findings. Frontiers in endocrinology. 2022;13:810782. 43. Zidoune H, Ladjouze A, Chellat-Rezgoune D, Boukri A, Dib SA, Nouri N, et al. Novel Genomic Variants, Atypical Phenotypes and Evidence of a Digenic/Oligogenic Contribution to Disorders/Differences of Sex Development in a Large North African Cohort. Frontiers in genetics. 2022;13:900574. 44. Li L, Gao F, Fan L, Su C, Liang X, Gong C. Disorders of Sex Development in Individuals Harbouring MAMLD1 Variants: WES and Interactome Evidence of Oligogenic Inheritance. Frontiers in endocrinology. 2020;11:582516. 45. Baxter RM, Arboleda VA, Lee H, Barseghyan H, Adam MP, Fechner PY, et al. Exome sequencing for the diagnosis of 46,XY disorders of sex development. The Journal of clinical endocrinology and metabolism. 2015;100(2):E333-44. 46. Jameson SA, Lin YT, Capel B. Testis development requires the repression of Wnt4 by Fgf signaling. Developmental biology. 2012;370(1):24-32. 47. Li Y, Zheng M, Lau YF. The sex-determining factors SRY and SOX9 regulate similar target genes and promote testis cord formation during testicular differentiation. Cell Rep. 2014;8(3):723- 33. 48. Flück CE, Audí L, Fernández-Cancio M, Sauter KS, Martinez de LaPiscina I, Castaño L, et al. Broad Phenotypes of Disorders/Differences of Sex Development in MAMLD1 Patients Through Oligogenic Disease. Frontiers in genetics. 2019;10:746. 49. Kinuta K, Tanaka H, Moriwake T, Aya K, Kato S, Seino Y. Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology. 2000;141(4):1317-24. 50. Djurovic J, Stamenkovic G, Todorovic J, Aleksic N, Stojkovic O. Polymorphisms and haplotypes in VDR gene are associated with female idiopathic infertility. Hum Fertil (Camb). 2020;23(2):101-10. 51. Cariboni A, Hickok J, Rakic S, Andrews W, Maggi R, Tischkau S, et al. Neuropilins and their ligands are important in the migration of gonadotropin-releasing hormone neurons. J Neurosci. 2007;27(9):2387-95. 52. Cariboni A, Davidson K, Rakic S, Maggi R, Parnavelas JG, Ruhrberg C. Defective gonadotropin-releasing hormone neuron migration in mice lacking SEMA3A signalling through NRP1 and NRP2:

All rights reserved. No reuse allowed without permission.

 implications for the aetiology of hypogonadotropic hypogonadism. Human molecular genetics. 2011;20(2):336-44. 53. Qiao J, Han B. Diseases caused by mutations in luteinizing hormone/chorionic gonadotropin receptor. Prog Mol Biol Transl Sci. 2019;161:69-89. 54. McTaggart SJ, Algar E, Chow CW, Powell HR, Jones CL. Clinical spectrum of Denys-Drash and Frasier syndrome. Pediatr Nephrol. 2001;16(4):335-9. 55. Dabrowski E, Armstrong AE, Leeth E, Johnson E, Cheng E, Gosiengfiao Y, et al. Proximal Hypospadias and a Novel WT1 Variant: When Should Genetic Testing Be Considered? Pediatrics. 2018;141(Suppl 5):S491-s5. 56. Wang Y, Li Q, Xu J, Liu Q, Wang W, Lin Y, et al. Mutation analysis of five candidate genes in Chinese patients with hypospadias. European journal of human genetics : EJHG. 2004;12(9):706-12. 57. Bagchi D, Andrade J, Shupnik MA. A new role for wilms tumor protein 1: differential activities of + KTS and -KTS variants to regulate LHβ transcription. PloS one. 2015;10(1):e0116825. 58. Bouma GJ, Hudson QJ, Washburn LL, Eicher EM. New Candidate Genes Identified for Controlling Mouse Gonadal Sex Determination and the Early Stages of Granulosa and Sertoli Cell Differentiation1. Biology of Reproduction. 2010;82(2):380-9. 59. Beverdam A, Koopman P. Expression profiling of purified mouse gonadal somatic cells during the critical time window of sex determination reveals novel candidate genes for human sexual dysgenesis syndromes. Human molecular genetics. 2006;15(3):417-31. 60. Guo MH, Plummer L, Chan YM, Hirschhorn JN, Lippincott MF. Burden Testing of Rare Variants Identified through Exome Sequencing via Publicly Available Control Data. Am J Hum Genet. 2018;103(4):522-34. 61. Eggers S, Sinclair A. Mammalian sex determination—insights from humans and mice. Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology. 2012;20(1):215-38. 62. Portnoi MF, Dumargne MC, Rojo S, Witchel SF, Duncan AJ, Eozenou C, et al. Mutations involving the SRY-related gene SOX8 are associated with a spectrum of human reproductive anomalies. Human molecular genetics. 2018;27(7):1228-40. 63. Miller WL, Huang N, Pandey AV, Flück CE, Agrawal V. P450 oxidoreductase deficiency: a new disorder of steroidogenesis. Ann N Y Acad Sci. 2005;1061:100-8. 64. Nie X, Arend LJ. Pkd1 is required for male reproductive tract development. Mech Dev. 2013;130(11-12):567-76. 65. Liu B, Chen SC, Yang YM, Yan K, Qian YQ, Zhang JY, et al. Identification of novel PKD1 and PKD2 mutations in a Chinese population with autosomal dominant polycystic kidney disease. Scientific reports. 2015;5:17468. 66. Brown TR, Lubahn DB, Wilson EM, French FS, Migeon CJ, Corden JL. Functional characterization of naturally occurring mutant androgen receptors from subjects with complete androgen insensitivity. Molecular endocrinology (Baltimore, Md). 1990;4(12):1759-72. 67. Camats N, Flück CE, Audí L. Oligogenic Origin of Differences of Sex Development in Humans. International journal of molecular sciences. 2020;21(5). 68. Délot EC, Vilain E. Towards improved genetic diagnosis of human differences of sex development. Nature reviews Genetics. 2021;22(9):588-602. 69. Bouty A, Ayers KL, Pask A, Heloury Y, Sinclair AH. The Genetic and Environmental Factors Underlying Hypospadias. Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation. 2015;9(5):239- 59. 70. Martinez de LaPiscina I, Flück CE. Genetics of human sexual development and related disorders. Current opinion in pediatrics. 2021;33(6):556-63. 71. Martinez de LaPiscina I, de Mingo C, Riedl S, Rodriguez A, Pandey AV, Fernández-Cancio M, et al. GATA4 Variants in Individuals With a 46,XY Disorder of Sex Development (DSD) May or May

- Not Be Associated With Cardiac Defects Depending on Second Hits in Other DSD Genes. Frontiers in endocrinology. 2018;9:142.
- 72. Zhang W, Shi J, Zhang C, Jiang X, Wang J, Wang W, et al. Identification of gene variants in 130
- Han Chinese patients with hypospadias by targeted next-generation sequencing. Molecular genetics & genomic medicine. 2019;7(8):e827.
- 73. Kolesinska Z, Acierno J, Jr., Ahmed SF, Xu C, Kapczuk K, Skorczyk-Werner A, et al. Integrating
- clinical and genetic approaches in the diagnosis of 46,XY disorders of sex development. Endocrine connections. 2018;7(12):1480-90.
- 74. 60th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Hormone research in paediatrics. 2022;95(suppl 2)(2):1-616.
- 75. Gentilin B, Forzano F, Bedeschi MF, Rizzuti T, Faravelli F, Izzi C, et al. Phenotype of five cases
- of prenatally diagnosed campomelic dysplasia harboring novel mutations of the SOX9 gene.
- Ultrasound Obstet Gynecol. 2010;36(3):315-23.

Table 1. Phenotype of the DSD patients harbouring the *NR5A1*/SF-1 p.Gly146Ala variant. Further details including biochemical data are given in Supplementary table 2.



F, female; hCG, human chorionic gonadotropin; M, male; MRI, magnetic resonance imaging; ND, not determined; T, testosterone; US, ultrasound; y, years. <sup>a</sup>Origin of the patients: <sup>1</sup>Spanish; <sup>2</sup>African;<sup>3</sup>Asian. <sup>b</sup>None of external genitalia was classified according to (74).

<b>Patient</b>	Chromosome position	Gene (Name)	Variant	<b>Type</b>	dbSNP	Zygosity	Previously reported <sup>a</sup>
1	4:1807384	FGFR3 (Fibroblast Growth Factor Receptor 3)	c.1633 1634del; p.Cys545Hisfs*17	frameshift deletion	<b>ND</b>	het	
	5:5232601	ADAMTS16 (ADAM Metallopeptidase with Thrombospondin Type 1 Motif 16)	c.1822 1823del; p.His608*	stopgain	<b>ND</b>	het	
	19:7184641	<b>INSR</b> (Insulin Receptor)	c.660 661del; p.Pro220Hisfs*4	frameshift deletion	<b>ND</b>	het	
3	2:120989442	GLI2 (GLI Family Zinc Finger 2)	c.3528G>T; p.Gln1176His	nonsynonymous SNV	rs139686081	het	
	8:60743055	CHD7 (Chromodomain Helicase DNA Binding Protein 7)	c.1623C>A; p.His541Gln	nonsynonymous SNV	<b>ND</b>	het	
	11:77181567	MYO7A (Myosin VIIA)	c.2882G>A; p.Gly961Asp	nonsynonymous SNV	rs199575418	het	
	12:47865148	<b>VDR</b> (Vitamin D Receptor)	c.176C>T; p.Thr59Ile	nonsynonymous SNV	rs145002466	het	
6	10:33330774	NRP1 (Neuropilin 1)	c.182C>A; p.Pro61Gln	nonsynonymous SNV	<b>ND</b>	het	
8	2:48698724	<b>LHCGR</b> (Luteinizing Hormone/Choriogonadotropin Receptor)	c.757T>C; p.Ser253Pro	nonsynonymous SNV	<b>ND</b>	hom	
9	11:32428517	WT1 (WT1 Transcription Factor)	c.764T>A; p.Met255Lys	nonsynonymous SNV	rs377573993	het	
10	9:114275766	COL27A1 (Collagen Type XXVII Alpha 1 Chain)	c.3715C>T; p.Arg1239Trp	nonsynonymous SNV	rs143724625	het	
	15:41564270	TYRO3 (TYRO3 Protein Tyrosine Kinase)	c.666 667insCACTGCCTGCAGCCC CCTTCAACATCACC; p.Ala223Hisfs*21	frameshift insertion	<b>ND</b>	het	
11	16:984721	SOX8 (SRY-Box Transcription Factor 8)	c.676A>C; p.Thr226Pro	nonsynonymous SNV	<b>ND</b>	het	
12	7:75985941	POR (Cytochrome P450 Oxidoreductase)	c.1679C>T; p.Thr560Met	nonsynonymous SNV	rs574694698	het	
	16:2114399	PKD1 (Polycystin 1, Transient Receptor Potential Channel Interacting)	c.2624C>T; p.Pro875Leu	nonsynonymous SNV	<b>ND</b>	het	
	16:30737182	SRCAP (Snf2 Related CREBBP Activator Protein)	c.7142G>A; p.Arg2381His	nonsynonymous SNV	rs765139685	het	
	17:72123563	SOX9 (SRY-Box Transcription Factor 9)	c.710dup; p.Pro238Thrfs*14	frameshift insertion	<b>ND</b>	het	Campomelic dysplasia (75)
13	X:67721837	AR (Androgen Receptor)	c.2323C>T; p.Arg775Cys	nonsynonymous SNV	rs137852562	hemi	AIS (66)
14	11:77194460	MYO7A (Myosin VIIA)	c.4259G>A; p.Arg1420His	nonsynonymous SNV	rs568337942	het	
	16:984739	SOX8 (SRY-Box Transcription Factor 8)	c.694A>C; p.Lys232Gln	nonsynonymous SNV	rs1596200787	het	

Table 2. Additional gene variants identified in the DSD patients harbouring the *NR5A1*/SF-1 p.Gly146Ala variant.

AIS, androgen insensitivity syndrome; Hemi, hemizygous; Het, heterozygous; Hom, homozygous; ND, not determined; POI, primary ovarian insufficiency. Variants classified as pathogenic, likely pathogenic or as of unknown significance according to the ACMG (American College of Medical Genetics) are highlighted in bold.<br>
<sup>a</sup>Previously associated disease to the specific var

All rights reserved. No reuse allowed without permission.

Figure 1. Algorithm of genetic workup. A. Mode of genetic analysis, e.g. panel and whole exome sequencing (WES). Three patients were identified with pathogenic variants in LHCGR, WT1 and AR by panel analysis and were not further analyzed by whole-exome sequencing (WES). B. Filtering algorithm of genetic data. Steps used for variant filtering after WES of eleven DSD patients harboring the NR5A1/SF-1 p.Gly146Ala variant are depicted (letters a to f). Final candidates and their possible impact are listed and characterized in Table 2 and Supplementary Table 3.



All rights reserved. No reuse allowed without permission.





Figure 3. Genetic variants identified in 14 DSD patients harboring the *NR5A1*/SF-1 p.Gly146Ala variant illustrated with respect to the known pathways of male and female sex determination and differentiation. The scheme shows an overview of involved genes and their currently assumed relationship to sexual development. Genes with variants identified by whole exome sequencing in the patients have specific colors. In dark blue: candidate genes in patient 1; in brown: candidate genes in patient 3; in green: candidate genes in patient 6; in yellow: candidate genes in patient 8; in dark red: candidate genes in patient 9; in red: candidate genes in patient 10; in pink: candidate genes in patient 11; in light blue: candidate genes in patient 12; in purple: candidate genes in patient 13; in orange: candidate genes in patient 14; in dark grey: known genes involved in sexual development. Interrogation mark (?): function/timing/location is not clear; arrows: activation; inhibitors: inhibition; lines: interaction/partnership; dashed lines/arrows: hormone production.

